66329-1-Ig

antibody from Proteintech Group

Targeting: SRD5A1

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

66329-1-Ig

Provider

Proteintech Group

Product name

SRD5A1 antibody

Antibody type

Monoclonal

Description

SRD5A1 antibody (Cat. #66329-1-Ig) is a mouse monoclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IHC, WB,ELISA.

Reactivity

Human

Host

Mouse

Conjugate

Unconjugated

Isotype

IgG

Antibody clone number

1D5D8

Vial size

20ul, 150ul

References

Submitted references

Restraining SRD5A1 combined with BRD4 inhibitor delaying prostate cancer progression by decreasing AR expression.

Liu Y, Qian D, Ding Y, Wu D, Tang C, Xu C, Chen X
International journal of biological macromolecules 2026 Jan;338(Pt 2):149810

---

Inhibition of Colorectal Cancer by Perillaldehyde Through Targeting SRD5A1 to Induce Autophagy via the PI3K/AKT Pathway.

Leng Z, Zhang Y, Guo M, Chen Y, Wang Z
Drug design, development and therapy 2025;19:6399-6412

---

Alterations in glucocorticoid homeostasis following sleeve gastrectomy.

Moser SO, Moscalu A, Roberts CF, Winter DV, Joos FL, Gómez C, Sheu EG, Odermatt A
bioRxiv : the preprint server for biology 2025 Sep 5;

---

Germline-Somatic Liaison Dictates Cancer Subtypes via de novo Steroid Biosynthesis.

Gasperini P, Alaimo A, Stringa B, Chung YM, Ciani Y, Lorenzin F, Fracassi G, Zekri Y, Orlando F, Quaini O, Gregoricchio S, Petris G, Casini A, Barbieri CE, Zwart W, Cereseto A, Sharifi N, Lunardi A, Demichelis F
Cancer discovery 2025 Oct 6;15(10):2166-2184

---

The estrous cycle modulates early-life adversity effects on mouse avoidance behavior through progesterone signaling.

Laham BJ, Murthy SS, Hanani M, Clappier M, Boyer S, Vasquez B, Gould E
Nature communications 2022 Dec 7;13(1):7537

---

Effects of Curcumin Combined With the 5-alpha Reductase Inhibitor Dutasteride on LNCaP Prostate Cancer Cells.

Nakayama A, Ide H, Lu Y, Takei A, Fukuda K, Osaka A, Arai G, Horie S, Okada H, Saito K
In vivo (Athens, Greece) 2021 May-Jun;35(3):1443-1450

---

Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma.

Dou R, Qian J, Wu W, Zhang Y, Yuan Y, Guo M, Wei R, Yang S, Jurczyszyn A, Janz S, Beksac M, Gu C, Yang Y
Cell death & disease 2021 Feb 24;12(2):206

---

Steroid 5α-Reductase Type I Induces Cell Viability and Migration via Nuclear Factor-κB/Vascular Endothelial Growth Factor Signaling Pathway in Colorectal Cancer.

Wei R, Zhong S, Qiao L, Guo M, Shao M, Wang S, Jiang B, Yang Y, Gu C
Frontiers in oncology 2020;10:1501

---

Expression of steroidogenic enzymes and metabolism of steroids in COS-7 cells known as non-steroidogenic cells.

Nozaki M, Haraguchi S, Miyazaki T, Shigeta D, Kano N, Lei XF, Kim-Kaneyama JR, Minakata H, Miyazaki A, Tsutsui K
Scientific reports 2018 Feb 1;8(1):2167

---

Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer.

Ide H, Lu Y, Noguchi T, Muto S, Okada H, Kawato S, Horie S
Cancer science 2018 Apr;109(4):1230-1238